Mr. Meckler has held a variety of roles over in both large and small biopharma companies. Most recently, Mr. Meckler was the CEO of Cocrystal Pharma, transforming it into a clinical company. Additionally, he has held led companies like QLT, Inc. and Cypress Bioscience through transformational times. Mr. Meckler is currently a director and former Chairman of Retrophin. Mr. Meckler started his career in life sciences with Pfizer, Inc., eventually becoming a member of the Corporate Finance Leadership Team and overseeing acquisition and divestiture activities. Mr. Meckler holds a B.S. in Industrial Management and a M.S. in Industrial Administration from the Tepper School of Business at Carnegie Mellon University. Additionally, he received his J.D. from Fordham University’s School of Law.
Dr. Nadav Navon has been with us since March 2006 and has served as our COO since July 2017. Before that he served as our Executive Vice President of Research & Development and Operations since March 2015. Prior to his service with us, Dr. Navon headed the analytical and quality assurance operations at Sharon Laboratories Ltd., a chemical company that develops and manufactures raw materials for the pharmaceutical, cosmetic and food industries, from 2001 to 2006. Prior to that, Dr. Navon led a number of research and development projects in the Negev’s Nuclear Research Center. Dr. Navon has a Ph.D. in inorganic and analytical chemistry, and an MBA and a BSc in chemistry, each from Ben-Gurion University in Beer-Sheva, Israel.
Mr. Nir Sassi has been our Chief Financial Officer since August 2016. Prior to serving as our Chief Financial Officer, he served as our VP Finance commencing in March 2010. Prior to his service with us, Mr. Sassi served as a Senior Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.
Dr. Anna Hotovely-Salomon is serving as our VP Clinical Affairs. Prior to joining Intec Pharma, she held a position of Senior Global Clinical Project Manager at Quintiles, managed large cross-functional project teams to support Phase II/III studies. Anna also led Phases I, II and III clinical trials as Global Operational Manager in TEVA Pharmaceutical Company and prior to that she served as R&D Project Manager of Tissue Regeneration. Anna has over 18 years of experience in Biotechnology and gained considerable experience in managing Clinical Trials. Anna holds a PhD degree in Biomedical Polymers, Applied Chemistry from the Hebrew University, Jerusalem, Israel.